- Home
- TGTX vs BKH Comparison
TGTX vs BKH Comparison
Compare TGTX & BKH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TGTX
- BKH
- Stock Information
- Founded
- TGTX 1993
- BKH 1941
- Country
- TGTX United States
- BKH United States
- Employees
- TGTX N/A
- BKH N/A
- Industry
- TGTX Biotechnology: Pharmaceutical Preparations
- BKH Electric Utilities: Central
- Sector
- TGTX Health Care
- BKH Utilities
- Exchange
- TGTX Nasdaq
- BKH Nasdaq
- Market Cap
- TGTX 5.5B
- BKH 4.4B
- IPO Year
- TGTX 1995
- BKH N/A
- Fundamental
- Price
- TGTX $33.65
- BKH $65.38
- Analyst Decision
- TGTX Strong Buy
- BKH Hold
- Analyst Count
- TGTX 6
- BKH 3
- Target Price
- TGTX $47.50
- BKH $66.00
- AVG Volume (30 Days)
- TGTX 1.5M
- BKH 627.9K
- Earning Date
- TGTX 11-04-2025
- BKH 11-05-2025
- Dividend Yield
- TGTX N/A
- BKH 4.13%
- EPS Growth
- TGTX N/A
- BKH N/A
- EPS
- TGTX 0.36
- BKH 3.97
- Revenue
- TGTX $454,069,000.00
- BKH $2,242,900,000.00
- Revenue This Year
- TGTX $82.13
- BKH $10.45
- Revenue Next Year
- TGTX $49.01
- BKH $3.32
- P/E Ratio
- TGTX $92.64
- BKH $16.48
- Revenue Growth
- TGTX 30.96
- BKH 5.40
- 52 Week Low
- TGTX $22.61
- BKH $54.92
- 52 Week High
- TGTX $46.48
- BKH $65.59
- Technical
- Relative Strength Index (RSI)
- TGTX 48.14
- BKH 73.98
- Support Level
- TGTX $34.01
- BKH $64.17
- Resistance Level
- TGTX $35.52
- BKH $62.11
- Average True Range (ATR)
- TGTX 1.28
- BKH 1.01
- MACD
- TGTX -0.24
- BKH 0.45
- Stochastic Oscillator
- TGTX 16.02
- BKH 95.03
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
About BKH Black Hills Corporation
Black Hills Corp is a U.S.-based energy company that operates through its Electric Utilities and Gas Utilities segment. These segments operate in states in the Midwest and mountain regions in the U.S. The company's customers include residential, commercial, industrial, and municipal consumers. These customers are residential. Black Hills derives the majority of its revenue from its utility business group, specifically from gas utilities.